Lviv clinical bulletin 2017, 4(20): 40-53


The content of some vasoactive humoral-metabolic factors in patients with cirrhosis and their participation in pathogenesis of comorbid syntropical damages of cardiovascular system

М. Abrahamovych, О. Abrahamovych, M. Farmaha

Danylo Halytsky Lviv National Medical University

Introduction. Liver cirrhosis is an inveterate polyetiological disease that regards to the 6 main reasons of patients’ mortality at the age of 35-60. The management of treatment and prediction for patients with cirrhosis particularly are defined by syntropic polymorbidal damages of other organs and systems among which are circulatory system diseases – cardiomyopathy and arterial hypotension – the most frequent ones. Firts of all, the improvement of diagnostics and treatment of those patients supposes the studying their pathogenesis. For the time being, the most probable pathogenetic chains are endothelial dysfunction, imbalance in renin-angiotensin-aldosterone system, and also overproduction of brain natriuretic peptide.

Aim. To examine the content of vasoactive humoral-metabolic factors, i.e. endothelium-dependent (cyclic guanosine monophosphate, endothelin-1), indexes of renin-aldosterone system (renin, aldosterone) and brain natriuretic hormone in blood plasma in patients with cirrhosis and discover their participation in pathogenesis of comorbid syntropical damages of cardiovascular system.

Materials and methods. Randomly with the previous stratification due to the presence of cirrhosis there were 603 patients (445 men (73.8 %) and 158 women (26.2 %) at the age of 19-80 (average age 49.2 ± 10.6) who were treated in the Lviv Regional Hepatological Centre, they had the complex clinical-laboratorial and instrumental research of all organs and systems before treatment due to the orders of the Ministry of Healthcare of Ukraine. Using these results we have seperate 490 (81.3 %) cirrhosis patients with extrahepatic damages of cardiovascular system (investigational group which is stratified into 3 subgroups, i.e. those who have only syntropic cardiomyopathy (103 patients) – group A, only syntropic hypotension (89 patients) – group B and others (306 patients)), and also those who don’t have the damages of cardiovascular system (113 patients; 18.7 %) – the comparison group). Randomly, to achieve the aim the part of the patients from every subgroup (30 patients from A-group,  27 – from B-group and 25 from group of comparison) were screened for the content of the vasoactive humoral-metabolic factorsm. There were 17 almost healthy volunteers of the same gender and age in the control group.

Results and discussion. The patients of both investigational groups have reasonably higher number of vasoactive humoral-metabolic factors. In particular, patients with cirrhosis and syntopetic cardiomyopathy dominate the effects of endothelin-1, renin and brain natriuretic peptide, and in patients with cirrhosis and syntropic arterial hypotension – cyclic guanosine monophosphate and aldosterone are the main factors. Additionally we recorded the pathological interaction among vasoactive material. Unlike of the results in comparison group, in patients with liver cirrhosis and syntropic cardiomyopathy, the local vasoactive compounds are in such interactions with each other that result in hyperactivity of the renin-angiotensin-aldosterone system and endothelial dysfunction with a significant increase in both vasoconstrictor endothelin-1 and vasodilator NO, and in patients with liver cirrhosis and arterial hypotension – to severe endothelial dysfunction with overproduction of NO.

Conclusions. Cyclic guanosine monophosphate, endothelin-1, renin, aldosterone, and brain natriuretic peptide, have a pathological effect on each other and are involved in the pathogenesis of syntropic damages of the circulatory system in patients with liver cirrhosis. In patients with cirrhosis and syntropic cardiomyopathy, heart damage occurs through toxic myocardial damage due to excessive effects of renin, endothelin-1, and brain natriuretic peptide with the onset of systolic and diastolic dysfunction and overload of the heart with blood volume. And in patients with cirrhosis and syntropic arterial hypotension, the damage occurs due to the endothelial dysfunction with excessive cyclic guanosine monophosphate and hyperaldosteronism, which leads to the expansion of peripheral vessels, the depositing of excess blood in the organs and, consequently, the decrease in the effective volume of circulation blood.


  1. Abrahamovych MO, Abrahamovych OO, Farmaha ML, Tolopko SI. Characteristics of syntropic polymorbide lesions in patients with cirrhosis of the liver and their dependence on the severity of the disease. Contemporary Gastroenterology. 2013;4:23-30. (Ukrainian).
  2. Babak OY, Kolesnykova EV, Dubrov KY. Modern ideas about cirrhotic cardiomyopathy. Ukrainian therapeutic journal. 2009;2:102-108. (Ukrainian).
  3. Voloshyn OI, Prysyazhnyuk OI, Prysyazhnyuk VP. Defeat of the cardiovascular system in patients with cirrhosis of the liver not of viral origin. Clinical and Experimental Pathology. 2009;8:106-110. (Ukrainian).
  4. Ivashkin VT, Morozova MA, Maevskaya MV. Hepatopulmonary syndrome. Transplantology. 2009;2:5-8. (Russian).
  5. Kovalenko VN, Talaeva TV, Bratus’ VV. Renin-angiotensin system in cardiac pathology. Part 1. Ukrainian Cardiological Journal. 2012;3:105-129. (Russian).
  6. Kursov SB, Myhnevych KH, Lyhosub NV, Skoroplet SN. Hepatopulmonary syndrome. Emergency medicine. 2009;24:75-82. (Russian).
  7. Pentuyk NO, Harchenko NV. The role of endotoxin and vasoactive metabolites in the development of decompensatory cirrhosis of the liver. Hepatology. 2010;3:32-40. (Ukrainian).
  8. Serhieni OV, Panina SS, Voytchak TH at al. Epidemiological aspects and causes of disability due to chronic hepatitis. Gastroenterology: interagency collection. 2007;38:26-32. (Ukrainian).
  9. Talaeva TV, Bratus’ VV. Renin-angiotensin system in cardiovascular pathology: the possibility of pharmacological correction. Ukrainian medical chapel. 2012;1(87):115-122. (Ukrainian).
  10. Shypulin VP. Liver Cirrhosis: Therapy Issues. Medical case = Medical case. 2007;1-2:36-40. (Ukrainian).
  11. Shchekotova AP, Tuev AV, Shchekotov VV at al. Interrelation of indices of endothelial dysfunction and syndromes arising in chronic diffuse liver diseases. Kazan Medical Journal. 2010;91(2):143-148. (Russian).
  12. Baik SK, Lee SS. Cirrhotic cardiomyopathy: causes and consequences. J Gastroenterol Hepatol. 2004;19(1 Suppl):185-190. https://doi.org/10.1111/j.1440-1746.2004.03639.x
  13. Hu LS, George J, Wang JH. Current concepts on the role of nitric oxide in portal hypertension. World J Gastroenterol. 2013;19(11):1707-1717. https://doi.org/10.3748/wjg.v19.i11.1707
  14. Iwakiri Y, Kim MY. Nitric oxide in liver diseases. Trends Pharmacol Sci. 2015;36(8):524-536. https://doi.org/10.1016/j.tips.2015.05.001
  15. Iwakiri Y. Nitric oxide in liver fibrosis: The role of inducible nitric oxide synthase. Clin Mol Hepatol. 2015;21(4):319-325. https://doi.org/10.3350/cmh.2015.21.4.319
  16. Koch DG, Bogatkevich G, Ramshesh V, Lemasters JJ, Uflacker R, Reuben A. Elevated levels of endothelin-1 in hepatic venous blood are associated with intrapulmonary vasodilatation inhumans. Dig Dis Sci. 2012;57(2):516-523. https://doi.org/10.1007/s10620-011-1905-6
  17. Miсano C, Garcia-Tsao G. Portal Hypertension. Gastroenterol Clin North Am. 2010;39(3):681-695. https://doi.org/10.1016/j.gtc.2010.08.015
  18. Munter K, Kirchengast M. The role of endothelin receptor antagonists in cardiovascular pharmacotherapy. Expert Opin Emerg Drugs. 2001;6:3-11. https://doi.org/10.1517/14728214.6.1.3
  19. Radvan M, Svoboda P, Radvanová J. Brain natriuretic peptide in decompensation of liver cirrhosis in non-cardiac patients. Hepatogastroenterology. 2009;56(89):181-185.
  20. Rothermund L, Pinto YM, Hocher B, Vetter R, Leggewie S, Kobetamehl P et al. Cardiac endothelin system impairs left ventricular function in rennin-dependent hypertension via sarcoplasmic reticulum Ca2+ uptake. Circulation. 2000;102(3):1582-1588. https://doi.org/10.1161/01.CIR.102.13.1582
  21. Torregrosa M, Aguadé S, Dos L, Segura R, Gónzalez A, Evangelista A et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol. 2005;42(1):68-74. https://doi.org/10.1016/j.jhep.2004.09.008
  22. Unger T, Li J. The role of the renin-angiotensin-aldosterone system in heart failure. J Renin Angiotensin Aldosterone Syst. 2004;5(1 Suppl):S7-10. https://doi.org/10.3317/jraas.2004.024
  23. Vatter H, Zimmermann M, Tesanovic V, Raabe A, Schilling L, Seifert V. Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist clinically effective for the treatment of cerebral vasospasm. Part I: inhibitory effect on endothelin(A) receptor-mediated contraction. J Neurosurg. 2005;102(6):1101-1107. https://doi.org/10.3171/jns.2005.102.6.1101
  24. Wereszczynka-Siemiatkowska U, Swidnicka-Siergiejko A, Siemiatkowski A, Bondyra Z, Wasielica-Berger J, Mroczko B et al. Endothelin 1 and transforming growth factor-β1 correlate with liver function and portal pressure in cirrhotic patients. Cytokine. 2015;76(2):144-151. https://doi.org/10.1016/j.cyto.2015.05.025
  25. Wong F, Siu S, Liu P, Blendis LM. Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis. Clin Sci (Lond). 2001;101(6):621-628. https://doi.org/10.1042/cs1010621
  26. Yildiz R, Yildirim B, Karincaoglu M, Harputluoglu M, Hilmioglu F. Brain natriuretic peptide and severity of disease in non-alcoholic cirrhotic patients. J Gastroenterol Hepatol. 2005;20(7):1115-1120. https://doi.org/10.1111/j.1440-1746.2005.03906.x